At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Empagliflozin +1 moredrug
Likely dose
Empagliflozin 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Dorzagliatin and Empagliflozin in Subjects with Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating Empagliflozin and Dorzagliatin for Patients. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and empagliflozin given alone and in combination will be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatients
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartApr 2019
Primary CompletionMar 2020
TodayJul 2026
First PostedJan 2, 2019
Enrollment StartApr 18, 2019
Primary CompletionMar 15, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.5 years ago
Interventions
Empagliflozindrug
Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
Dorzagliatindrug
Glucokinase activator currently under development